Logo image of IRBT

IROBOT CORP (IRBT) Stock Fundamental Analysis

NASDAQ:IRBT - Nasdaq - US4627261005 - Common Stock - Currency: USD

2.56  -0.18 (-6.57%)

After market: 2.56 0 (0%)

Fundamental Rating

1

Overall IRBT gets a fundamental rating of 1 out of 10. We evaluated IRBT against 64 industry peers in the Household Durables industry. IRBT has a bad profitability rating. Also its financial health evaluation is rather negative. IRBT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IRBT had negative earnings in the past year.
IRBT had a negative operating cash flow in the past year.
In multiple years IRBT reported negative net income over the last 5 years.
IRBT had negative operating cash flow in 4 of the past 5 years.
IRBT Yearly Net Income VS EBIT VS OCF VS FCFIRBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

IRBT's Return On Assets of -52.31% is on the low side compared to the rest of the industry. IRBT is outperformed by 93.75% of its industry peers.
Industry RankSector Rank
ROA -52.31%
ROE N/A
ROIC N/A
ROA(3y)-34.67%
ROA(5y)-17.81%
ROE(3y)-150.96%
ROE(5y)-86.07%
ROIC(3y)N/A
ROIC(5y)N/A
IRBT Yearly ROA, ROE, ROICIRBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 21.06%, IRBT is doing worse than 70.31% of the companies in the same industry.
IRBT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for IRBT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.94%
GM growth 5Y-13.55%
IRBT Yearly Profit, Operating, Gross MarginsIRBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

0

2. Health

2.1 Basic Checks

IRBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IRBT has been increased compared to 1 year ago.
The number of shares outstanding for IRBT has been increased compared to 5 years ago.
The debt/assets ratio for IRBT is higher compared to a year ago.
IRBT Yearly Shares OutstandingIRBT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRBT Yearly Total Debt VS Total AssetsIRBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.01, we must say that IRBT is in the distress zone and has some risk of bankruptcy.
IRBT has a worse Altman-Z score (-1.01) than 84.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.01
ROIC/WACCN/A
WACC10.84%
IRBT Yearly LT Debt VS Equity VS FCFIRBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 0.55 indicates that IRBT may have some problems paying its short term obligations.
IRBT's Current ratio of 0.55 is on the low side compared to the rest of the industry. IRBT is outperformed by 96.88% of its industry peers.
IRBT has a Quick Ratio of 0.55. This is a bad value and indicates that IRBT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of IRBT (0.39) is worse than 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.55
Quick Ratio 0.39
IRBT Yearly Current Assets VS Current LiabilitesIRBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.74% over the past year.
IRBT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -28.05%.
Measured over the past years, IRBT shows a very negative growth in Revenue. The Revenue has been decreasing by -10.90% on average per year.
EPS 1Y (TTM)21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.45%
Revenue 1Y (TTM)-28.05%
Revenue growth 3Y-24.19%
Revenue growth 5Y-10.9%
Sales Q2Q%-32.29%

3.2 Future

The Earnings Per Share is expected to grow by 33.34% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.89% on average over the next years. This is quite good.
EPS Next Y50.57%
EPS Next 2Y33.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.32%
Revenue Next 2Y9.89%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IRBT Yearly Revenue VS EstimatesIRBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
IRBT Yearly EPS VS EstimatesIRBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRBT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRBT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRBT Price Earnings VS Forward Price EarningsIRBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRBT Per share dataIRBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

IRBT's earnings are expected to grow with 33.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.34%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IRBT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IROBOT CORP

NASDAQ:IRBT (5/21/2025, 8:06:49 PM)

After market: 2.56 0 (0%)

2.56

-0.18 (-6.57%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryHousehold Durables
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04
Inst Owners59.66%
Inst Owner Change-4.27%
Ins Owners4%
Ins Owner Change15.43%
Market Cap78.41M
Analysts45.71
Price Target11.22 (338.28%)
Short Float %24.88%
Short Ratio3.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-33.81%
Min EPS beat(2)-50.53%
Max EPS beat(2)-17.08%
EPS beat(4)1
Avg EPS beat(4)19.02%
Min EPS beat(4)-50.53%
Max EPS beat(4)152.06%
EPS beat(8)4
Avg EPS beat(8)7.13%
EPS beat(12)5
Avg EPS beat(12)-79.21%
EPS beat(16)7
Avg EPS beat(16)-49.56%
Revenue beat(2)0
Avg Revenue beat(2)-13.54%
Min Revenue beat(2)-20.34%
Max Revenue beat(2)-6.73%
Revenue beat(4)0
Avg Revenue beat(4)-10.93%
Min Revenue beat(4)-20.34%
Max Revenue beat(4)-3.48%
Revenue beat(8)2
Avg Revenue beat(8)-8.48%
Revenue beat(12)2
Avg Revenue beat(12)-13.48%
Revenue beat(16)4
Avg Revenue beat(16)-10.35%
PT rev (1m)0%
PT rev (3m)-4.1%
EPS NQ rev (1m)1.75%
EPS NQ rev (3m)-80.65%
EPS NY rev (1m)-42.29%
EPS NY rev (3m)-118.66%
Revenue NQ rev (1m)-7.41%
Revenue NQ rev (3m)-17.5%
Revenue NY rev (1m)-4.39%
Revenue NY rev (3m)-6.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.94
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS20.68
BVpS-0.03
TBVpS-5.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.06%
FCFM N/A
ROA(3y)-34.67%
ROA(5y)-17.81%
ROE(3y)-150.96%
ROE(5y)-86.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.94%
GM growth 5Y-13.55%
F-Score2
Asset Turnover1.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.55
Quick Ratio 0.39
Altman-Z -1.01
F-Score2
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)11.65%
Cap/Depr(5y)43.11%
Cap/Sales(3y)0.46%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.45%
EPS Next Y50.57%
EPS Next 2Y33.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.05%
Revenue growth 3Y-24.19%
Revenue growth 5Y-10.9%
Sales Q2Q%-32.29%
Revenue Next Year-6.32%
Revenue Next 2Y9.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.65%
OCF growth 3YN/A
OCF growth 5YN/A